NCT06037473 The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg
| NCT ID | NCT06037473 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Children's Hospital |
| Condition | Growth Hormone Treatment |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,600 participants |
| Start Date | 2023-08-01 |
| Primary Completion | 2029-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,600 participants in total. It began in 2023-08-01 with a primary completion date of 2029-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in children, explore and analyze the factors affecting the efficacy of PEG-rhGH and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world PEG-GH treatment. A database registration study was developed.
Eligibility Criteria
Inclusion Criteria: Patients with endogenous growth hormone deficiency, Turner Syndrome, SGA, idiopathic short stature, etc. treated with polyethylene glycol recombinant human growth hormone injection Exclusion Criteria: Patients with serious heart and lung, blood system, malignant tumors and other diseases or systemic infections, immune function is low and Persons with mental illness;
Contact & Investigator
Bingyan Cao, Dr.
PRINCIPAL INVESTIGATOR
Beijing Children's Hospital
Frequently Asked Questions
Who can join the NCT06037473 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Growth Hormone Treatment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06037473 currently recruiting?
Yes, NCT06037473 is actively recruiting participants. Contact the research team at chunxiugong@163.com for enrollment information.
Where is the NCT06037473 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06037473 clinical trial?
NCT06037473 is sponsored by Beijing Children's Hospital. The principal investigator is Bingyan Cao, Dr. at Beijing Children's Hospital. The trial plans to enroll 2,600 participants.